Roche’s Gazyva Extends Leukemia Patients’ Survival
This article is for subscribers only.
Roche Holding AG’s newly approved medicine Gazyva helped patients with chronic lymphocytic leukemia live almost a year longer without their disease progressing than its top-seller, Rituxan, in a clinical trial.
Patients taking Gazyva along with the chemotherapy chlorambucil lived for a median 26.7 months without their cancer spreading, compared with 15.2 months for those on Rituxan plus chlorambucil, Basel, Switzerland-based Roche said today. The data, from the last of three stages of testing necessary for U.S. approval, will be presented next month at the American Society of Hematology meeting in New Orleans.